BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35078046)

  • 1. 2-Methoxydiol derivatives as new tubulin and HDAC dual-targeting inhibitors, displaying antitumor and antiangiogenic response.
    Sun M; Qin J; Kang Y; Zhang Y; Ba M; Yang H; Duan Y; Yao Y
    Bioorg Chem; 2022 Mar; 120():105625. PubMed ID: 35078046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
    Wang Y; Sun M; Wang Y; Qin J; Zhang Y; Pang Y; Yao Y; Yang H; Duan Y
    Eur J Med Chem; 2021 Dec; 225():113790. PubMed ID: 34454126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and bioevaluation of novel stilbene-based derivatives as tubulin/HDAC dual-target inhibitors with potent antitumor activities in vitro and in vivo.
    Zhu H; Zhu W; Liu Y; Gao T; Zhu J; Tan Y; Hu H; Liang W; Zhao L; Chen J; Zhu Z; Chen J; Xu J; Xu S
    Eur J Med Chem; 2023 Sep; 257():115529. PubMed ID: 37269670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.
    Zhang X; Kong Y; Zhang J; Su M; Zhou Y; Zang Y; Li J; Chen Y; Fang Y; Zhang X; Lu W
    Eur J Med Chem; 2015 May; 95():127-35. PubMed ID: 25805446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and biological evaluation of dual tubulin/HDAC inhibitors based on millepachine for treatment of prostate cancer.
    Xie S; Leng J; Zhao S; Zhu L; Zhang M; Ning M; Zhao B; Kong L; Yin Y
    Eur J Med Chem; 2024 Mar; 268():116301. PubMed ID: 38452727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of new 2-methoxyestradiol derivatives: Potent inhibitors of angiogenesis and tubulin polymerization.
    Sun M; Zhang Y; Qin J; Ba M; Yao Y; Duan Y; Liu H; Yu D
    Bioorg Chem; 2021 Aug; 113():104988. PubMed ID: 34034135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure⁻Activity Relations of New Inhibitors of HDAC and/or Tubulin Function.
    Schmitt F; Gosch LC; Dittmer A; Rothemund M; Mueller T; Schobert R; Biersack B; Volkamer A; Höpfner M
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
    Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a novel piperlongumine analogue as a microtubule polymerization inhibitor with potent anti-angiogenic and anti-metastatic efficacy.
    Qin J; Li H; Wang X; Zhang Y; Duan Y; Yao Y; Yang H; Sun M
    Eur J Med Chem; 2022 Dec; 243():114738. PubMed ID: 36162214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel HDAC/Tubulin Dual Inhibitor: Design, Synthesis and Docking Studies of α-Phthalimido-Chalcone Hybrids as Potential Anticancer Agents with Apoptosis-Inducing Activity.
    Mourad AAE; Mourad MAE; Jones PG
    Drug Des Devel Ther; 2020; 14():3111-3130. PubMed ID: 32848361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis and anti-leukaemia activity of novel indole derivatives as potent colchicine binding site inhibitors.
    Yao Y; Huang T; Wang Y; Wang L; Feng S; Cheng W; Yang L; Duan Y
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):652-665. PubMed ID: 35109719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel non-toxic and anti-angiogenic α-fluorinated chalcones as potent colchicine binding site inhibitors.
    Sun M; Yuan M; Kang Y; Qin J; Zhang Y; Duan Y; Wang L; Yao Y
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):339-354. PubMed ID: 34979843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of novel bis-substituted aromatic amide dithiocarbamate derivatives as colchicine site tubulin polymerization inhibitors with potent anticancer activities.
    Sun YX; Song J; Kong LJ; Sha BB; Tian XY; Liu XJ; Hu T; Chen P; Zhang SY
    Eur J Med Chem; 2022 Feb; 229():114069. PubMed ID: 34971875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect.
    Ibrahim TS; Hawwas MM; Malebari AM; Taher ES; Omar AM; Neamatallah T; Abdel-Samii ZK; Safo MK; Elshaier YAMM
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):802-818. PubMed ID: 33730937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of novel benzodiazepine derivatives as anticancer agents through inhibition of tubulin polymerization in vitro and in vivo.
    Pang Y; Lin H; Ou C; Cao Y; An B; Yan J; Li X
    Eur J Med Chem; 2019 Nov; 182():111670. PubMed ID: 31499359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton.
    Sun S; Zhao W; Li Y; Chi Z; Fang X; Wang Q; Han Z; Luan Y
    Bioorg Chem; 2021 Mar; 108():104652. PubMed ID: 33497873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and bioevaluation of 2,7-diaryl-pyrazolo[1,5-a]pyrimidines as tubulin polymerization inhibitors.
    Liu R; Zhang S; Huang M; Guo Z; Li L; Li M; Wu L; Guan Q; Zhang W
    Bioorg Chem; 2021 Oct; 115():105220. PubMed ID: 34352709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer.
    Bär SI; Dittmer A; Nitzsche B; Ter-Avetisyan G; Fähling M; Klefenz A; Kaps L; Biersack B; Schobert R; Höpfner M
    Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35485292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a Dual Tubulin and Neuropilin-1 (NRP1) Inhibitor with Potent In Vivo Anti-Tumor Activity via Pharmacophore-based Docking Screening, Structure Optimization, and Biological Evaluation.
    Zheng L; Zou Y; Xie T; Wu X; Tan Y; Mei S; Geng Y; Chen S; Xu S; Niu MM
    J Med Chem; 2023 Dec; 66(23):16187-16200. PubMed ID: 38093696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and Preclinical Evaluation of Indole Triazole Conjugates as Microtubule Targeting Agents that are Effective against MCF-7 Breast Cancer Cell Lines.
    Yele V; Pindiprolu SKSS; Sana S; Ramamurty DSVNM; Madasi JRK; Vadlamani S
    Anticancer Agents Med Chem; 2021; 21(8):1047-1055. PubMed ID: 32981511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.